Gilead Sciences Inc. has signed an agreement with Compugen Ltd. to exclusively license Compugen’s preclinical antibody program against IL-18 binding protein, including the COM-503 drug candidate. COM-503 is a high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby inhibiting cancer growth.